SRR2932826
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.400
- HYPOXIA+0.390
- APICAL_JUNCTION+0.320
- PANCREAS_BETA_CELLS+0.310
- WNT_BETA_CATENIN_SIGNALING+0.290
- HEDGEHOG_SIGNALING+0.270
- MYOGENESIS+0.240
- GLYCOLYSIS+0.230
- UV_RESPONSE_DN+0.230
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.350
- E2F_TARGETS-0.340
- ALLOGRAFT_REJECTION-0.320
- INTERFERON_GAMMA_RESPONSE-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- ADIPOGENESIS-0.280
- IL6_JAK_STAT3_SIGNALING-0.280
- G2M_CHECKPOINT-0.250
- SPERMATOGENESIS-0.240
- BILE_ACID_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613779 | — | D | 0.833 |
| 2 | TCGA-BA-6868-01B-12R-1915-07 | — | — | 0.820 |
| 3 | SRR8613703 | — | D | 0.815 |
| 4 | TCGA-77-8145-01A-11R-2247-07 | — | cohortSQ1 | 0.811 |
| 5 | SRR975596 | — | — | 0.806 |
| 6 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.802 |
| 7 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.782 |
| 8 | MNG527 | — | — | 0.778 |
| 9 | SRR8613758 | — | C | 0.777 |
| 10 | TCGA-OL-A97C-01A-32R-A41B-07 | — | A | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |